ArticlePloS one2020

An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.

Alexandre Perrier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.